What are the risks of injectable breast augmentation?
The risks primarily stem from two aspects: the physicochemical properties of polyacrylamide hydrogel and issues related to injection technique.
Physical property issues: After injection, polyacrylamide hydrogel diffuses randomly within tissues. It forms either extremely thin capsules or fails to encapsulate entirely, preventing confinement to a fixed area. This leads to a "honeycomb-like structure" with multiple cystic cavities or migration of the hydrogel to other body regions, causing noticeable breast asymmetry or deformity.Additionally, the hydrogel infiltrates surrounding glandular and muscular tissues, making complete removal difficult and management highly problematic.
Chemical Properties: The monomer components within polyacrylamide hydrogels exhibit neurotoxicity, causing varying degrees of damage to the nervous system and kidneys.Although Omedin exhibits higher purity than Ingelfer and maintains lower monomer content, its polyacrylamide composition cannot be guaranteed against degradation within the complex human environment. Consequently, the hazards posed by resulting toxic monomers remain incalculable. How should injectable breast augmentation be managed?
Prior to the ban on Omedin and similar substances, numerous small hospitals and cosmetic clinics in China extensively employed these agents for breast augmentation procedures.Over the past five years, approximately 300,000 women have undergone Omedin-based breast augmentation procedures, with many patients developing diverse complications. Consequently, the prevailing view among domestic plastic surgeons is early removal. However, some practitioners' inaccuracies in removal techniques or complication management have inflicted further harm on those seeking beauty.